openPR Logo
Press release

Axial Spondyloarthritis Therapeutics Market Size was ~USD 9 Million in 2023, estimated DelveInsight

11-21-2024 09:52 PM CET | Health & Medicine

Press release from: ABNewswire

Axial Spondyloarthritis Therapeutics Market Size was ~USD 9

DelveInsight's "Axial Spondyloarthritis Market Insights, Epidemiology and Market Forecast-2034" report delivers an in-depth understanding of the indication axial spondyloarthritis, historical and forecasted epidemiology as well as the axial spondyloarthritis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Discover Key Insights into the Axial Spondyloarthritis Market with DelveInsight's In-Depth Report @ Axial Spondyloarthritis Market Size [https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Axial Spondyloarthritis Market Report

* In November 2024:- UCB Biopharma SRL- A Multicenter, Open-Label Extension Study to Asses the Long-Term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Study Participants With Active Axial Spondyloarthritis, Ankylosing Spondylitis, and Nonradiographic Axial Spondyloarthritis. The purpose of the study is to demonstrate the long-term safety, tolerability and efficacy of bimekizumab in patients with active axial spondyloarthritis (axSpA, also known as radiographic axSpa (r-axSpA)) including ankylosing spondylitis (AS) and nonradiographic axial spondyloarthritis (nr-axSpa).
* As per DelveInsight's estimates, the total diagnosed population of non-radiographic axial spondyloarthritis in the US was around 569,000 cases in 2023.
* Among EU4 and UK countries, Germany had the highest number of prevalent axial spondyloarthritis cases in 2023, followed by Spain.
* The leading Axial Spondyloarthritis Companies such as Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
* Promising Axial Spondyloarthritis Therapies such as SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol , and others

Stay ahead in the Axial Spondyloarthritis Therapeutics Market with DelveInsight's Strategic Report @ Axial Spondyloarthritis Market Outlook [https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Axial Spondyloarthritis Epidemiology Segmentation in the 7MM

* Total Axial Spondyloarthritis Prevalent Cases
* Total Axial Spondyloarthritis Diagnosed Prevalent Cases
* Axial Spondyloarthritis Gender-specific Cases
* Axial Spondyloarthritis Gene-specific Cases
* Axial Spondyloarthritis Age-specific Cases
* Total Axial Spondyloarthritis Treated Cases

Download the report to understand which factors are driving Axial Spondyloarthritis epidemiology trends @ Axial Spondyloarthritis Prevalence [https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Axial Spondyloarthritis Marketed Drugs

* SIMPONI (golimumab): Janssen Pharmaceuticals

SIMPONI is a human IgG1? monoclonal antibody specific for human tumor necrosis factor-alpha (TNF--a) that exhibits multiple glycoforms. It was created using genetically engineered mice immunized with human TNF, resulting in an antibody with human-derived antibody variable and constant regions. It binds to both the soluble and transmembrane bioactive forms of human TNFa. This interaction prevents the binding of TNFa to its receptors, thereby inhibiting the biological activity of TNFa (a cytokine protein). This molecule is produced by a recombinant cell line cultured by continuous perfusion and is purified by a series of steps that include measures to inactivate and remove viruses.

* XELJANZ (tofacitinib): Pfizer

XELJANZ, a film-coated immediate-release tablet, is the first and only oral JAK inhibitor approved in the European Union for five indications. It is prescribed for adults with active AS who have not responded adequately to conventional therapy and for adults with moderately to severely active RA after failure or intolerance to disease-modifying antirheumatic drugs (DMARDs). Additionally, it is used for adults with active PsA after DMARD failure or intolerance and for adults with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to conventional therapy or a biologic agent.

Axial Spondyloarthritis Market Outlook

The market size of axial spondyloarthritis in the seven major markets is expected to increase substantially from 2024. The United States accounts for the largest market size of axial spondyloarthritis, in comparison to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan. Among EU4 and the UK, Germany has the largest market size, followed by Spain, with France having the smallest market size. In 2023, the total market size for axial spondyloarthritis therapies was approximately USD 9 million, with the majority occupied by conventional treatments.

Get In-Depth Knowledge on Axial Spondyloarthritis Market Trends and Forecasts with DelveInsight @ Axial Spondyloarthritis Treatment Market [https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Axial Spondyloarthritis Therapies and Companies

* SIMPONI (golimumab): Janssen Pharmaceuticals
* XELJANZ (tofacitinib): Pfizer
* Bimekizumab: UCB Biopharma
* CC-99677: Celgene
* ABY- 035: Inmagene Biopharmaceuticals
* Filgotinib: Galapagos NV
* KHK4827: Kyowa Kirin Co., Ltd.
* Ixekizumab: Eli Lilly and Company
* Golimumab: Merck Sharp & Dohme LLC
* etanercept: Pfizer
* Bimekizumab: UCB Biopharma
* Secukinumab: Novartis
* SHR0302: Jiangsu HengRui Medicine
* Certolizumab Pegol: UCB Biopharma

Axial Spondyloarthritis Market Drivers

* The introduction of novel products
* Increasing prevalence
* Awareness about the Disease
* Research and development strategies

Axial Spondyloarthritis Market Barriers

* High-cost treatment
* Delay in Diagnosis
* Immunogenicity
* Loss of patent exclusivity
* Availability of generics
* Poor Quality of Life

Unlock Strategic Insights with DelveInsight's Comprehensive Axial Spondyloarthritis Market Report @ Axial Spondyloarthritis Market Drivers and Barriers [https://www.delveinsight.com/sample-request/axial-spondyloarthritis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Axial Spondyloarthritis Market Report

* Coverage- 7MM
* Axial Spondyloarthritis Companies- Janssen Pharmaceuticals, Pfizer, UCB Biopharma, Celgene, Inmagene Biopharmaceuticals, Galapagos NV, Kyowa Kirin Co., Ltd., Eli Lilly and Company, Merck Sharp & Dohme LLC, Pfizer, Novartis, Jiangsu HengRui Medicine, UCB Biopharma, and others
* Axial Spondyloarthritis Therapies- SIMPONI (golimumab), XELJANZ (tofacitinib), Bimekizumab, CC-99677, ABY- 035, Filgotinib, KHK4827, Ixekizumab, Golimumab, etanercept, Secukinumab, SHR0302, Certolizumab Pegol, and others.
* Axial Spondyloarthritis Therapeutic Assessment: Axial Spondyloarthritis Current marketed and Lipodystrophy Emerging Therapies
* Axial Spondyloarthritis Market Dynamics: Axial Spondyloarthritis Market drivers and Lipodystrophy Market Barriers

Table of Content

1. Key Insights

2. Report Introduction

3. Axial Spondyloarthritis (axSpA) Market Overview at a Glance

4. Methodology

5. Executive Summary

6. Disease Background and Overview

7. Treatment of Axial Spondyloarthritis (axSpA)

8. Epidemiology and Patient Population

9. Patient Journey

10. Marketed Therapies

11. Market Analysis

12. KOL Views

13. SWOT Analysis

14. Unmet Needs

15. Market Access and Reimbursement

16. Appendix

17. DelveInsight Capabilities

18. Disclaimer

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=axial-spondyloarthritis-therapeutics-market-size-was-usd-9-million-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/case-study/in-licensing-opportunity



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Axial Spondyloarthritis Therapeutics Market Size was ~USD 9 Million in 2023, estimated DelveInsight here

News-ID: 3750299 • Views:

More Releases from ABNewswire

League Sources Confirm Spurs and Bucks Engaged in Giannis Antetokounmpo Trade Discussions; San Antonio Declares Stephon Castle and Dylan Harper Off Limits
League Sources Confirm Spurs and Bucks Engaged in Giannis Antetokounmpo Trade Di …
San Antonio, TX - In a significant development that marks the most substantive movement in years of speculation, league sources confirm that the San Antonio Spurs and Milwaukee Bucks have recently discussed a potential trade centered around two-time MVP Giannis Antetokounmpo. The conversations, described as focused and serious, represent the closest the NBA has come to a legitimate Antetokounmpo trade framework since rumors began circulating in 2020. The news was first
Ecuadorian Rainforest Highlights Key Botanical Categories Influencing Winter Formulation Planning
Ecuadorian Rainforest Highlights Key Botanical Categories Influencing Winter For …
Company emphasizes mushrooms, adaptogens, calming herbs, superfruits, and seasonal botanicals as product developers prepare early 2026 launches. Clifton, NJ - Ecuadorian Rainforest, LLC has released its December focus on botanical ingredients supporting winter formulation activity across the nutraceutical, functional food, and beverage sectors. As brands enter a new development cycle, interest continues to center around ingredients that align with seasonal consumer preferences and year-round product innovation. Industry conversations throughout the winter period
St. Pete's Largest Chanukah Celebration Returns: FLAME Set to Ignite the City's Young Jewish Community
St. Pete's Largest Chanukah Celebration Returns: FLAME Set to Ignite the City's …
FLAME is the largest Jewish young-professional Chanukah party in the area St. Petersburg, Fla. - The brightest night of the season is back. FLAME, the region's largest Chanukah celebration for Jewish young professionals, returns on Thursday, Dec. 18, at Studio@620, 620 1st Ave S, St. Petersburg, starting at 7:30 p.m. Hosted by the Chabad Jewish Center of St. Petersburg, FLAME has quickly become the signature holiday event for Jewish young adults across
From Concept to Completion: The Custom Home Building Process in Joplin, MO
From Concept to Completion: The Custom Home Building Process in Joplin, MO
Image: https://www.abnewswire.com/upload/2025/12/5d47d6a5afda50373383532cb9d682b6.jpg Building a custom home in Joplin, MO, is the ultimate dream for many families. It is the chance to create a space that perfectly matches your lifestyle, from the kitchen layout to the bedroom count. This journey is exciting, but it is also a complex, multi-stage process. Understanding the steps, from the first sketch to the final coat of paint, is key. A professional general contractor guides you through

All 5 Releases


More Releases for Axial

Transformative Trends Impacting the Axial Lead Capacitors Market Landscape: Inno …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts. How Large Will the Axial Lead Capacitors Market Size By 2025? The market size for axial lead capacitors has seen robust growth in the past years. The market is projected to increase from $0.98 billion in 2024 to $1.04 billion in 2025, with a compound annual growth rate (CAGR)
Six Axial Simulation Table Market Size Analysis by Application, Type, and Region …
According to Market Research Intellect, the global Six Axial Simulation Table market under the Internet, Communication and Technology category is expected to register notable growth from 2025 to 2032. Key drivers such as advancing technologies, changing consumer behavior, and evolving market dynamics are poised to shape the trajectory of this market throughout the forecast period. The six axial simulation table market is experiencing notable growth due to its expanding use in
Axial Flow Pump Market Fueled By Growing Freshwater Needs: An Emerging Driver Tr …
The Axial Flow Pump Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Projected Growth of the Axial Flow Pump Market? The Axial Flow Pump Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034.
Axial Spondyloarthritis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Axial Spondyloarthritis Pipeline Insight 2024" report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Axial Spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Axial Spondyloarthritis Research. Learn more about
Axial Flow Pump Market Reaches $44B by 2031
Axial Flow Pump Market Scope: Key Insights : Axial Flow Pump Market size was valued at USD 29.83 billion in 2022 and is poised to grow from USD 31.14 billion in 2023 to USD 43.95 billion by 2031, growing at a CAGR of 4.4% during the forecast period (2024-2031). Access the full 2024 Market report for a comprehensive understanding @https://www.skyquestt.com/report/axial-flow-pump-market In-Depth Exploration of the global Axial Flow Pump Market: This report
Axial Extensometers Market Size, Share, Development by 2024
Global Info Research offers a latest published report on Axial Extensometers Market Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global Axial Extensometers players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years. To analyze the Axial Extensometers with respect to individual growth